Therefore, blood levels of the identified cachexigenic factors might help identify early PC individuals with unexplained weight loss, and therapies targeting S100A9 activity might attenuate both PC-induced cachexia and PCDM, reducing PC-induced complications. Here, S100A9 is linked to pachyonychia congenita.